Abstract
We developed an assay which permits measurement of aspartate carbamoyltransferase (ACTase) activity. Cytosol from human peripheral blood mononuclear cells was used as the enzyme source. Using [14C]carbamoyl phosphate as the radiolabeled substrate, the formation of [14C]carbamoyl aspartate was quantitated by high performance liquid chromatography (HPLC) using an anion-exchange column with UV detection at 200-280 nm and an on-line liquid scintillation detector. A gradient method from an initially low concentration of ammonium phosphate, 1 mM (pH 3.0), to a higher concentration, 38 mM (pH 4.5), was used. The apparent K(m) values of carbamoyl phosphate and aspartate were 58 μM and 1.9 mM, respectively. ACTase inhibition by N-(phosphonacetyl)-1-aspartate (PALA) was consistent with a competitive model with respect to carbamoyl phosphate. The assay conditions were optimized to permit measurement of ACTase activity prior to and following therapy with PALA; ACTase was inhibited in a dose-dependent manner. This HPLC method permits direct quantitation of both the product of the reaction and the initial integrity of the substrate, [14C]carbamoyl phosphate, which is unstable in aqueous solutions.
Original language | English (US) |
---|---|
Pages (from-to) | 545-554 |
Number of pages | 10 |
Journal | Anti-Cancer Drugs |
Volume | 4 |
Issue number | 5 |
DOIs | |
State | Published - 1993 |
Externally published | Yes |
Keywords
- Aspartate carbamoyltransferase
- Biochemical monitoring
- HPLC
- N-(phosphonoacetyl)-1-aspartate
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research